INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024
February 06, 2024 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as...
INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer
May 08, 2023 08:00 ET
|
INmune Bio, Inc.
Represents First Ever Natural Killer Immunotherapy trial in Metastatic Castration-Resistant Prostate CancerWebinar at 11AM ET on Friday, May 12. BOCA RATON, Fla., May 08, 2023 (GLOBE...
INmune Bio to Present at BIO CEO & Investor Conference
February 06, 2019 09:00 ET
|
INmune Bio, Inc.
LA JOLLA, CA, Feb. 06, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (Nasdaq: INMB) (“INmune” or the “Company”), an immunotherapy company focused on developing therapies that harness the patient’s...
INmune Bio Announces Publication of Myeloid-Derived Suppressor Cells (MDSC) Report in the Cell’s Trends in Pharmacological Sciences Journal
December 07, 2018 09:00 ET
|
INmune Bio, Inc.
Manuscript highlights the vital role of MDSC in the tumor microenvironment (TME) LA JOLLA, Calif.,, Dec. 07, 2018 (GLOBE NEWSWIRE) -- INmune Bio Inc., an immunotherapy company developing...
INmune Nominated for Buzz of Bio Award at 2019 CEO & Investor Conference
December 04, 2018 08:30 ET
|
INmune Bio, Inc.
-Voting begins today: Click here to cast your vote- LA JOLLA, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- INmune Bio, Inc., an immunotherapy company focused on developing therapies that harness...